AEON Biopharma (AEON) Net Cash Flow (2021 - 2025)
AEON Biopharma (AEON) posted Net Cash Flow of -$2.9 million for Q4 2025, down 16.28% sequentially from -$2.5 million in Q3 2025, and down 457.44% YoY from $817193.8 in Q4 2024.
AEON Biopharma (AEON) Net Cash Flow (2021 - 2025) Analysis & Trends
AEON Biopharma has reported Net Cash Flow for 5 years, with the latest figure at -$2.9 million in Q4 2025.
- Quarterly Net Cash Flow fell 457.44% year-over-year to -$2.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $3.0 million (up 236.67% YoY) and the FY2025 annual result came in at $3.0 million, up 158.17% from the prior year.
- Net Cash Flow fell to -$2.9 million in Q4 2025 per AEON's latest filing, from -$2.5 million in the prior quarter.
- Over five years, Net Cash Flow peaked at $255.0 million in Q1 2023 and troughed at -$26.9 million in Q3 2022.
- A 5-year average of $10.6 million and a median of -$331169.0 in 2022 frame the typical range for Net Cash Flow.
- The sharpest annual moves came in 2022 and 2023: Net Cash Flow sank 8180.39% in 2022, then soared 77086.38% in 2023.
- Over 5 years, Net Cash Flow stood at -$166128.0 in 2021, then tumbled by 7397.23% to -$12.5 million in 2022, then dropped by 20.92% to -$15.1 million in 2023, then jumped by 96.52% to -$524000.0 in 2024, then sank by 457.44% to -$2.9 million in 2025.
- According to Business Quant data, Net Cash Flow over the past three periods registered -$2.9 million, -$2.5 million, and -$2.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -496,000.00 |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -37.14 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 225.59 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -2.83 Bn |
| 10 | AEON Biopharma | 10.06 Mn | 6.62 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -2.92 Mn |
| Dec 31, 2025 | -2.92 Mn |
| Sep 30, 2025 | -2.51 Mn |
| Sep 30, 2025 | -2.51 Mn |
| Jun 30, 2025 | -2.01 Mn |
| Jun 30, 2025 | -2.01 Mn |
| Mar 31, 2025 | 10.43 Mn |
| Mar 31, 2025 | 10.43 Mn |
| Dec 31, 2024 | -524,000.00 |
| Dec 31, 2024 | -524,000.00 |
| Sep 30, 2024 | 50,000.00 |
| Sep 30, 2024 | 50,000.00 |
| Jun 30, 2024 | 1.88 Mn |
| Jun 30, 2024 | 1.88 Mn |
| Mar 31, 2024 | -3.60 Mn |
| Mar 31, 2024 | -3.60 Mn |
| Sep 30, 2023 | -15.06 Mn |
| Sep 30, 2023 | -15.06 Mn |
| Jun 30, 2023 | 80,346.00 |
| Jun 30, 2023 | 80,346.00 |